M. O. Hamad et al. / Bioorg. Med. Chem. 14 (2006) 7051–7061
7061
14. Kozlowski, L. T.; Henningfield, J. E.; Keenan, R. M.; Lei,
H.; Leigh, G.; Jelinek, L. C.; Pope, M. A.; Haertzen, C. A.
J. Subst. Abuse Treat. 1993, 10, 171.
15. Mitchell, S. H.; Dewit, H.; Zacny, J. P. Behav. Pharmacol.
1995, 6, 359.
16. Glautier, S.; Clements, K.; White, J.; Taylor, C.; Stoler-
man, I. P. . Pharmacology 1996, 7, 144.
17. Smith, B. R.; Horan, J. T.; Gaskin, S.; Amit, Z. Psycho-
pharmacology (Berl.) 1999, 142, 408.
18. Watson, W. P.; Little, H. J. Neuropharmacology 1999, 38,
587.
19. So¨derpalm, B.; Ericson, M.; Olausson, P.; Blomqvist, O.;
Engel, J. A. Behav. Brain Res. 2000, 113, 85.
20. Keenan, R. M.; Hatsukami, D. K.; Pickens, R. W.; Gust, S.
W.; Strelow, L. J. Psychopharmacology (Berl.) 1990, 100,
77.
21. Hurt, R. D.; Offord, K. P.; Croghan, I. T.; Gomez-Dahl,
L.; Kottke, T. E.; Morse, R. M.; Melton, L. J. J. Am. Med.
Assoc. 1996, 275, 1097.
and analyzed by HPLC for the presence of codrug and
the two corresponding parent drugs, as well as for the
intermediate hydrolysis product, 23. Standards of co-
drug 25, codrug 26, NTX, 6-b-NTXOL, intermediate
23, and BUPOH were prepared in isotonic phosphate
buffer:acetonitrile (1:3, v/v) in the concentration range
0.1–2.0 lg/mL, and these solutions were used for the
generation of the respective calibration curves. Sample
recoveries were >95% for all the drugs, and data were
corrected for the respective extraction efficiencies. A
modification of the high-pressure liquid chromatograph-
ic (HPLC) assay reported by Hussain et al.30 was used
for the analysis of hydrolysis samples. The HPLC sys-
tem consisted of a Waters (Milford, MA, USA) model
717 Autosampler, two model 1525 pumps, and a model
2487 dual wavelength UV absorbance detector with
Millennium Chromatography software. A Brownlee
C18 reversed-phase Spheri-5 lm column (220 · 4.6 mm)
connected to a C18 reversed-phase guard column
(15 · 3.2 mm) was utilized and detection of solutes was
carried out at 215 nm. The mobile phase consisted of a
mixture of acetonitrile:0.1% trifluoroacetic acid adjusted
to pH 3.0 with triethylamine (50:50, v/v). The mobile
phase flow rate was 1.5 mL/min and 100 lL of hydroly-
sis sample was injected onto the column. The retention
times for each of the analytes were 14.60, 10.50, 2.86,
2.28, 5.20, and 4.56 min for codrug 25, codrug 26,
NTX, NTXOL, intermediate 23, and BUPOH,
respectively.
22. Frosch, D. L.; Shoptaw, S.; Nahom, D.; Jarvik, M. E.
Clin. Psychopharmacol. (Berl.) 2000, 8, 97.
23. Volpicelli, J. R.; Alterman, A. I.; Hayashida, M. Arch.
Gen. Psychiatry 1992, 49, 876.
24. Rukstalis, M. R.; Stromberg, M. F.; O’Brien, C. P.;
Volpicelli, J. R. Alcoholism: Clin. Exp. Res. 2000, 24, 1593.
25. Wang, D.; Raehal, K. M.; Bilsky, E. J.; Sadee, W. J.
Neurochem. 2001, 77, 1590.
26. Cooper, B. R.; Wang, C. M.; Cox, R. F.; Norton, R.; Shea,
V.; Ferris, R. M. Neuropsychopharmacology 1994, 11, 133.
27. Ascher, J. A.; Cole, J. O.; Colin, J. N.; Feighner, J. P.; Ferris,
R. M.; Fibiger, H. C.; Golden, R. N.; Martin, P.; Potter, W.
Z.; Richelson, E. J. Clin. Psychiatry 1995, 56, 395.
28. Sanchez, C.; Hyttel, J. Cell. Mol. Neurobiol. 1999, 19, 467.
29. Slemmer, J. E.; Martin, B. R.; Damaj, M. I. J. Pharmocol.
Exp. Ther. 2000, 295, 321.
Acknowledgment
30. Hussain, M. A.; Koval, C. A.; Myers, M. J.; Shami, E. G.;
Shefter, E. I. J. Pharm. Sci. 1987, 76, 356.
31. Olsen, L. D.; Klein, P.; Nelson, W. L.; Yao, Y. H.; Simon,
E. J. Med. Chem. 1990, 33, 737.
This work was funded by NIH Grant R01AA013853.
32. De Costa, B. R.; Ladarola, M. J.; Rothman, R. B.;
Berman, K. F.; George, C.; Newman, A. H.; Mahoubi, A.;
Jacobson, A. E.; Rice, K. C. J. Med. Chem. 1992, 35, 2826.
33. Hammell, D. C.; Hamad, M. O.; Vaddi, H. K.; Crooks, P.
A.; Stinchcomb, A. L. J. Controlled Release 2004, 97, 283.
34. Kiptoo, P.; Hammell, D. C.; Paudel, K.; Hamad, M. O.;
Crooks, P. A.; Stinchcomb, A. L. In vivo evaluation of a
transdermal codrug of 6-b-naltrexol linked to hydroxy-
bupropion in hairless guinea pigs (manuscript in
preparation).
35. Cooper, G. D.; Williams, B. J. Org. Chem. 1962, 27, 3717.
36. Fife, T. H.; Hutchins, J. E. C. J. Am. Chem. Soc. 1981,
103, 4194.
37. Ellaithy, M. M.; El-Ragehy, N. A.; El-Ghobashy, M. A.
Farmaco 2003, 58, 337.
References and notes
1. Sinkula, A. A.; Yalkowsky, S. H. J. Pharm. Sci. 1975, 64,
181.
2. Stella, V. J. Adv. Drug Delivery Rev. 1996, 19, 111.
3. Fleischer, D.; Bong, D.; Stewart, B. H. Adv. Drug Delivery
Rev. 1996, 19, 115.
4. Menger, F. C.; Rourk, M. J. J. Org. Chem. 1997, 62, 9083.
5. Leppa¨nen, J.; Huuskonen, J.; Nevalainen, T.; Gynther, J.;
Taipale, H.; Ja¨rvinen, T. J. Med. Chem. 2002, 45, 1379.
6. Di Stefano, A.; Sozio, P.; Cocco, A.; Iannitelli, A.;
Santucci, E.; Costa, M.; Pecci, L.; Nasuti, C.; Cantala-
messa, F.; Pinnen, F. J. Med. Chem. 2006, 49, 1486.
7. Jones, R. N.; Marshall, S. A.; Varnam, D. J. Diagn.
Microbiol. Infect. Dis. 1998, 32, 85.
38. Szeto, S. Y.; Burlinson, N. E.; Rettig, S. J.; Trotter, J.
J. Agric. Food Chem. 1989, 37, 1103.
39. Szeto, S. Y.; Burlinson, N. E.; Rahe, J. E.; Oloffs, P. C.
J. Agric. Food Chem. 1989, 37, 523.
8. Bryskier, A. Expert Opin. Invest. Drugs 1997, 6, 1479.
9. Hartley, S.; Wise, R. J. Antimicrob. Chemother. 1982, 10,
49.
10. Baltzer, B.; Binderup, E.; Von Daehne, W.; Godtfredsen,
W. O.; Hanson, K.; Nielson, B.; Sorensen, H.; Vangedal,
S. J. Antibiot. 1980, 33, 1183.
11. Cynkowska, G.; Cynkowski, T.; Al-Ghananeem, A. M.;
Guo, H.; Ashton, P.; Crooks, P. A. Bioorg. Med. Chem.
Lett. 2005, 15, 3524.
12. Howard-Sparks, M.; Al-Ghananeem, M. A.; Pearson, A.
P.; Crooks, P. A. J. Enz. Inhibit. Med. Chem. 2005, 20, 417.
13. Mello, N. K.; Mendelson, J. H.; Palmieri, S. L. Psycho-
pharmacology (Berl.) 1987, 93, 8.
40. Pothuluri, J. V.; Freeman, J. P.; Heinze, T. M.; Beger, R.
D.; Cerniglia, C. E. J. Agric. Food Chem. 2000, 48, 6138.
41. Jain, N.; Yalkowsky, S. H. J. Pharm. Sci. 2001, 90, 234.
42. Chatterjie, N.; Inturrisi, C. E.; Dayton, H. B.; Blumberg,
H. J. Med. Chem. 1975, 18, 490.
43. Perrine, D. M.; Ross, J. T.; Nervi, S. T.; Zimmerman, R.
H. J. Chem. Educat. 2000, 77, 1479.
44. Mehta, N. B. U.S. Patent 3,819,706, 1974.
45. Morgan, P. F.; Musso, D. L.; Partridge, J. J. U.S. Patent
Appl. Publ. 2003, U.S. 20030064988 A1, April 3rd.